

Patent Docket No. P1219P1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Timothy A. Stewart, et al.

Serial No.: 10/715,795

Filed: November 17, 2003

For:

FIBROBLAST GROWTH FACTOR-19 (FGF-19) NUCLEIC ACIDS AND

POLYPEPTIDES AND METHODS OFUSE FOR THE TREATMENT OF

OBESITY

Group Art Unit: 1646

Examiner: Olga N. Chernyshev

Confirmation No: 5748

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on

By: ______ Colden

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- [] 37 CFR §1.97(b) within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or before the mailing of the first Office action on the merits; or before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.
- [X] 37 CFR §1.97(c) by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.
- [] 37 CFR §1.97(d) after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. <u>07-0630</u> in the amount of <u>\$180.00</u> to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because a) [X] they were previously cited by or submitted to the Office in a prior application Serial No. 09,522,342 (ABN) filed 03/09/2000 which is a CIP of Serial No. 09/284,663 (ABN), filed 04/15/1999 which is a CON of Serial No. 09/158,342 (ABN), filed 09/21,1998 which claims benefit of Serial No. 60/066,840, filed 11/25/1997 and relied upon in this application for an earlier filing date under 35 USC §120 and/or because b)[] this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003 (1276 OG 55). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

	A concise explanation of relevance of the items listed on PTO-1449 is:						
	[X]	not given					
	0	given for each listed item					
	[]	given for only non-English language listed item(s) [Required]					
	[]	in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references					
	In acco	rdance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not					
be con	strued as	a representation that a search has been made.					

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. <u>07-</u> <u>0630</u>. A <u>duplicate copy of this sheet is enclosed</u>.

be construed to be an admission that the information cited in the statement is, or is considered to be,

Respectfully submitted,

GENENTECH, INC.

Date: May 29,2005

material to patentability as defined in 37 CFR § 1.56(b).

By: Cara M. Coburn

Reg. No. 46,631

Telephone No. (650) 467-6222

W TPE									Sheet $\underline{1}$ of $\underline{1}$					
FORM	PTO-1	449	2005	•			Atty Docket No.			Serial No. 10/715,795				
LIST	OF DIS	APR U 1 CLOSURIÉ CITED B	Y APPE CANT	Patent a	and Trademark Office	Applicant Goddard, A. et al								
(L	lse seve	CLOSURE CITED B	TMARK		Filing 17			Date Group 7 Nov 2003 1646						
U.S. PATENT DOCUMENTS														
xaminer iitials		Document Number	Date			Class	Subc	lass	Filing D	Date				
	*94	5,428,139		Kiefer et al.						10.12.91				
	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)													
	* 95	Weintraub and Bray, "Drug Treatment of Obesity" Med. Clin. of North America 73(1):237-249 (1989)												
														
•							10 							
			· •			 								
•				· · · · · · · · · · · · · · · · · · ·										
<u>.</u>														
		u .												
								·						
-										•				
			····					1						
			<u>.</u>											
									····		·			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Date Considered